

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular, or as to the action to be taken, you should consult your stockbroker or other licensed securities dealer, bank manager, solicitor, professional accountant or other professional advisers.

If you have sold or transferred all your shares in Consun Pharmaceutical Group Limited (the “Company”), you should at once hand this circular and the accompanying form of proxy to the purchaser(s) or transferee(s) or to the bank, stockbroker or licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



**(1) PROPOSED GRANT OF GENERAL MANDATES TO
ISSUE NEW SHARES AND REPURCHASE SHARES,
(2) PROPOSED ELECTION AND RE-ELECTION OF DIRECTORS,
(3) PROPOSED FINAL DIVIDEND
AND
(4) NOTICE OF ANNUAL GENERAL MEETING**

The notice convening the annual general meeting of the Company (the “AGM”) to be held at United Conference Centre, 10th Floor, United Center, 95 Queensway, Admiralty, Hong Kong on 31 May 2019 (Friday) at 10:00 a.m. is set out on pages 19 to 23 of this circular.

Whether or not you intend to attend the AGM in person, you are requested to complete, sign and return the accompanying form of proxy in accordance with the instructions printed thereon to the Company’s branch share registrar and transfer office in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish.

Hong Kong, 30 April 2019

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

“AGM”	the annual general meeting of the Company to be convened and held at United Conference Centre, 10th Floor, United Center, 95 Queensway, Admiralty, Hong Kong on 31 May 2019 (Friday) at 10:00 a.m., or where the context so admits, any adjournment thereof
“Articles of Association”	the articles of association of the Company as amended, modified or otherwise supplemental from time to time
“associates”	has the same meaning ascribed to it under the Listing Rules
“Board”	the board of Directors of the Company
“business day(s)”	a day (other than a Saturday, a Sunday or a public holiday) on which licensed banks are generally open for business in Hong Kong and the Stock Exchange is open for business of dealing in securities
“close associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Companies Law”	the Companies Law of the Cayman Islands (as amended, supplemented or otherwise modified from time to time)
“Company”	Consun Pharmaceutical Group Limited, a company incorporated under the laws of the Cayman Islands with limited liability with its Shares listed on the Stock Exchange
“controlling shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“core connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	director(s) of the Company
“Extension Mandate”	a general and unconditional mandate proposed to be granted to the Directors to the effect that any Shares repurchased under the Repurchase Mandate will be added to the total number of Shares which may be allotted and issued under the Issuing Mandate

DEFINITIONS

“Group”	the Company and its subsidiaries
“HKD”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Issuing Mandate”	a general and unconditional mandate proposed to be granted to the Directors to exercise the power of the Company to allot, issue or otherwise deal with Shares up to a maximum of 20% of the total number of the issued Shares of the Company as at the date of passing the relevant resolution at the AGM
“Latest Practicable Date”	23 April 2019, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
“Listing Date”	19 December 2013, on which dealings in Shares first commenced on the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange as amended, modified or otherwise supplemental from time to time
“Mr. An”	Mr. AN Yubao (安郁寶), the Chairman, an executive Director and a substantial shareholder of the Company
“Mr. Tang”	Mr. TANG Ning (唐寧), an executive Director of the Company
“Mr. Young”	Mr. YOUNG Wai Po, Peter, a former non-executive Director of the Company
“Ms. Chen”	Ms. CHEN Yujun (陳玉君), a proposed independent non-executive Director of the Company
“Ms. Li”	Ms. LI Qian (黎倩), the Vice Chairlady, Chief Executive Officer and a substantial shareholder of the Company
“PRC”	the People’s Republic of China which shall, for the purpose of this circular, exclude Hong Kong, the Macau Special Administrative Region and Taiwan

DEFINITIONS

“Professor Zhu”	Professor ZHU Quan (朱荃), an executive Director of the Company
“Repurchase Mandate”	a general and unconditional mandate proposed to be granted to the Directors to enable them during the relevant period to repurchase Shares, the total number of which shall not exceed 10% of the total number of the issued Shares of the Company as at the date of passing the relevant resolution at the AGM
“RMB”	the lawful currency of the PRC
“SFC”	the Securities and Futures Commission of Hong Kong
“SFO”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong
“Share(s)”	ordinary share(s) of HKD0.10 each in the share capital of the Company
“Share Option(s)”	share option(s) of the Company granted or to be granted by pursuant to the share option scheme adopted by the Company on 2 December 2013
“Shareholder(s)”	holder(s) of Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“substantial shareholder”	has the same meaning ascribed to it under the Listing Rules
“Takeovers Code”	the Hong Kong Code on Takeovers and Mergers
“%”	per cent.

LETTER FROM THE BOARD



康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1681)

Executive Directors:

Mr. AN Yubao (Chairman)
Ms. LI Qian (Vice Chairlady,
Chief Executive Officer)
Professor ZHU Quan
Mr. TANG Ning

Registered office:

Clifton House
75 Fort Street
P.O. Box 1350
Grand Cayman KY1-1108
Cayman Islands

Independent Non-executive Directors:

Mr. SU Yuanfu
Mr. FENG Zhongshi
Ms. CHENG Xinxin

*Head office and principal place of
business in the PRC:*

71, Dongpeng Avenue
Eastern section, Guangzhou Economic
and Technological Development District
Guangzhou, PRC

To the Shareholders

Dear Sir or Madam,

**(1) PROPOSED GRANT OF GENERAL MANDATES TO
ISSUE NEW SHARES AND REPURCHASE SHARES,
(2) PROPOSED ELECTION AND RE-ELECTION OF DIRECTORS,
(3) PROPOSED FINAL DIVIDEND
AND
(4) NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

The purpose of this circular is to provide you with information on the resolutions to be proposed at the AGM regarding (a) the grant to the Directors of the Issuing Mandate, the Repurchase Mandate and the Extension Mandate upon the expiry of the current general mandates to issue Shares and repurchase Shares granted to the Directors by ordinary resolutions passed at the annual general meeting of the Company held on 30 May 2018; (b) the election and re-election of the Directors; and (c) the proposed final dividend for the year ended 31 December 2018, and to give you notice of the AGM at which the resolutions will be proposed to consider and, if thought fit, approve such matters.

LETTER FROM THE BOARD

PROPOSED GRANT OF ISSUING MANDATE, REPURCHASE MANDATE AND EXTENSION MANDATE

Pursuant to the ordinary resolutions passed at the annual general meeting of the Company held on 30 May 2018, the Directors were granted (a) a general and unconditional mandate to allot, issue and deal with Shares not exceeding 20% of the total number of the issued Shares of the Company on the date of passing of the relevant ordinary resolution; and (b) a general and unconditional mandate to repurchase Shares with an aggregate number not exceeding 10% of the total number of the issued Shares of the Company on the date of passing of the relevant ordinary resolution; and (c) the power to extend the general mandate mentioned in (a) above by an amount representing the total number of the issued Shares repurchased by the Company pursuant to the mandate to repurchase securities referred to in (b) above.

The above general mandates will expire at the conclusion of the AGM. At the AGM, the following resolutions, among other matters, will be proposed:

- (a) to grant the Issuing Mandate to the Directors to exercise the powers of the Company to allot, issue and otherwise deal with the Shares up to a maximum of 20% of the total number of the issued Shares of the Company on the date of passing of such resolution;
- (b) to grant the Repurchase Mandate to the Directors to enable them to repurchase the Shares up to a maximum of 10% of the total number of the issued Shares of the Company on the date of passing of such resolution; and
- (c) to grant the Extension Mandate to the Directors to increase the total number of Shares which may be allotted and issued under the Issuing Mandate by an additional number representing such number of Shares repurchased under the Repurchase Mandate.

The full text of above resolutions are set out in resolutions numbered 5 to 7 as set out in the notice of the AGM contained in pages 19 to 23 of this circular.

Each of the Issuing Mandate, the Repurchase Mandate and the Extension Mandate will expire at the earliest of: (a) the conclusion of the next annual general meeting of the Company following the AGM; (b) the date by which the next annual general meeting is required by the Companies Law or the Articles of Association to be held; or (c) when the mandate given to the Directors thereunder is revoked or varied by ordinary resolution(s) of the Shareholders in a general meeting prior to the next annual general meeting of the Company.

Under the Listing Rules, the Company is required to give the Shareholders all information which is reasonably necessary to enable the Shareholders to make an informed decision as to whether to vote for or against the resolution in respect of the Repurchase Mandate at the AGM. An explanatory statement for such purpose is set out in Appendix I to this circular.

LETTER FROM THE BOARD

PROPOSED ELECTION AND RE-ELECTION OF THE DIRECTORS

Reference is made to the announcement of the Company dated 31 May 2018 in relation to the appointment of Mr. Tang by the Board as an executive Director of the Company. In accordance with article 112 of the Articles of Association, the Directors shall have the power from time to time and at any time to appoint any person as the Director either to fill a casual vacancy on the Board or as an addition to the existing Board. Any Director so appointed by the Board shall hold office only until the next following annual general meeting of the Company and shall then be eligible for re-election. Accordingly, Mr. Tang who was appointed as an executive Director by the Board with effect from 1 June 2018 shall be eligible for re-election at the AGM.

Further, as disclosed in the announcement of the Company dated 23 April 2019, an ordinary resolution will be proposed at the AGM to consider and approve the appointment of Ms. Chen as an independent non-executive Director with effect from the conclusion of the AGM.

The proposed election of Ms. Chen has been reviewed by the nomination committee of the Company which recommended to the Board that the election be proposed for the Shareholders' approval at the AGM based on the nomination policy and the diversity policy adopted by the Company. The nomination committee of the Company also assessed and reviewed the written confirmation received from Ms. Chen and formed the view that she has met the independence criteria as set out in Rule 3.13 of the Listing Rules and is considered to be independent.

Being a member of the Chinese Institute of Certified Public Accountants and possessing years of experience in auditing, accounting and corporate finance, Ms. Chen has the requisite professional qualifications or accounting expertise under Rule 3.10 of the Listing Rules. Further, Ms. Chen acted as the financial controller of the Group and therefore has in-depth understanding of the operations of the Group. Her work experience as a senior financial officer in other companies would allow her to contribute to the long-term development of the Group. In view of the above, her appointment as a Director would also contribute to diversity of the Board.

Pursuant to article 108 of the Articles of Association, at least one-third of the Directors for the time being shall retire from office by rotation at each annual general meeting provided that every Director shall be subject to retirement by rotation at least once every three years. A retiring director shall be eligible for re-election. Accordingly, Mr. An, Ms. Li and Professor Zhu shall retire by rotation at the AGM and, being eligible, offer themselves for re-election.

Particulars of each of the Directors proposed to be elected or re-elected at the AGM which are required to be disclosed by the Listing Rules are set out in Appendix II to this circular.

LETTER FROM THE BOARD

PROPOSED FINAL DIVIDEND

As stated in the announcement issued by the Company dated 20 March 2019 relating to the annual results of the Group for the year ended 31 December 2018, the Board recommended that, subject to Shareholders' approval in the AGM, the Company shall declare and distribute a final dividend of HKD0.2 per Share for the year ended 31 December 2018, which, if approved, is expected to be paid on or about Friday, 21 June 2019, to the Shareholders whose names appear on the register of members of the Company on Friday, 14 June 2019.

To determine shareholders' entitlement to the proposed final dividend, the register of members of the Company shall be closed from Tuesday, 11 June 2019 to Friday, 14 June 2019 (both days inclusive), during which period no share transfer will be registered. In order to qualify for the proposed final dividend, all share transfers accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, not later than 4:30 p.m. on Monday, 10 June 2019.

AGM

A notice of the AGM is set out on pages 19 to 23 of this circular.

At the AGM, resolutions will be proposed to the Shareholders to be considered at the AGM, including: (a) the grant to the Directors of the Issuing Mandate, the Repurchase Mandate and the Extension Mandate upon the expiry of the current general mandates to issue Shares and repurchase Shares granted to the Directors by ordinary resolutions passed at the annual general meeting of the Company held on 30 May 2018; (b) the election and re-election of the Directors; and (c) the proposed final dividend for the year ended 31 December 2018.

A form of proxy for use at the AGM is enclosed herewith. Whether or not you intend to attend the AGM in person, you are requested to complete, sign and return the accompanying form of proxy in accordance with the instructions printed thereon to the Company's branch share registrar and transfer office in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof should you so wish.

VOTING BY WAY OF POLL

Pursuant to Rule 13.39(4) of the Listing Rules and article 79 of the Articles of Association, all votes at the AGM will be taken by poll and the Company will announce the results of the poll in the manner prescribed under Rule 13.39(5) of the Listing Rules.

LETTER FROM THE BOARD

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein misleading.

RECOMMENDATION

The Board (including all independent non-executive Directors) consider that the proposed resolutions set out in the notice of the AGM including (a) the grant to the Directors of the Issuing Mandate, the Repurchase Mandate and the Extension Mandate upon the expiry of the current general mandates to issue Shares and repurchase Shares granted to the Directors by ordinary resolutions passed at the annual general meeting of the Company held on 30 May 2018; (b) the election and re-election of the Directors; and (c) the proposed final dividend for the year ended 31 December 2018, are in the interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends the Shareholders to vote in favour of the relevant resolutions to be proposed at the AGM.

GENERAL

Your attention is drawn to the additional information set out in the appendices to this circular.

MISCELLANEOUS

The English text of this circular shall prevail over the Chinese text for the purpose of interpretation.

Yours faithfully,
By Order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman and Executive Director

Hong Kong, 30 April 2019

This appendix serves as an explanatory statement, as required by the Listing Rules, to provide the requisite information to you for your consideration of the Repurchase Mandate.

LISTING RULES RELATING TO THE REPURCHASE OF SHARES

The Listing Rules permit companies whose primary listing is on the Stock Exchange to repurchase shares on the Stock Exchange and any other stock exchange on which securities of the company are listed and such exchange is recognised by the SFC subject to certain restrictions. Among such restrictions, the Listing Rules provide that the shares of such company must be fully paid up and all repurchases of shares by such company must be approved in advance by an ordinary resolution of shareholders, either by way of a general mandate or by specific approval of a particular transaction.

SHARE CAPITAL

As at the Latest Practicable Date, there were a total of 872,022,780 Shares in issue.

The Repurchase Mandate will enable the Directors to repurchase the Shares up to a maximum of 10% of the total number of the issued Shares of the Company on the date of passing the relevant ordinary resolution at the AGM. Subject to the passing of the proposed resolution granting the Repurchase Mandate and assuming that no further Shares will be issued or repurchased prior to the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 87,202,278 Shares.

The Repurchase Mandate, unless revoked or varied by way of an ordinary resolution of the Shareholders in general meeting, will expire at the conclusion of the next annual general meeting of the Company, which is expected to be convened on or before 30 June 2020.

FUNDING OF REPURCHASE

Repurchases must be funded out of funds legally available for the purpose in accordance with the Company's memorandum of association, the Articles of Association, the Listing Rules and the applicable laws of the Cayman Islands, which may include distributable profits of the Company.

REASONS FOR REPURCHASES

The Directors believe that the Repurchase Mandate is in the best interest of the Company and the Shareholders as a whole. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per share and/or earnings per Share and will only be made when the Directors believe that such repurchases will benefit the Company and the Shareholders as a whole.

EFFECT OF EXERCISING THE REPURCHASE MANDATE

There might be a material adverse impact on the working capital and/or gearing position of the Company as compared with the position disclosed in the most recent published audited accounts, in the event that the Repurchase Mandate were to be carried out in full at any time during the proposed repurchase period. However, the Directors do not intend to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements or the gearing position of the Company which in the opinion of the Directors are from time to time appropriate for the Company.

CONNECTED PERSONS

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their respective close associates (as defined in the Listing Rules) has a present intention to sell any Shares to the Company under the Repurchase Mandate if the same is approved by the Shareholders.

No core connected person (as defined in the Listing Rules) has notified the Company that he/she/it has a present intention to sell Shares to the Company, or has undertaken not to do so if the Repurchase Mandate is approved by the Shareholders.

UNDERTAKING

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the power to make repurchase pursuant to the Repurchase Mandate in accordance with the Listing Rules and the applicable laws of the Cayman Islands.

THE TAKEOVERS CODE AND MINIMUM PUBLIC HOLDING

If, as a result of a Shares repurchase, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of Rule 32 of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (as defined in the Takeovers Code) could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rule 26 or Rule 32 of the Takeovers Code.

As at the Latest Practicable Date and insofar the Directors are aware of, Mr. An is the founder of a discretionary trust holding, via an intermediate holding company, 197,324,000 Shares, representing approximately 22.63% of the total number of issued Shares of the Company. Mr. An, the trustee (and the intermediate holding company) of the discretionary trust in its capacity, Ms. Li, Double Grace International Limited, Mr. Young and Guido Limited (which is wholly owned by Mr. Young) are taken to be a concert party group and interested in a total of 450,150,078 Shares, representing 51.62% of the total number of issued Shares of the Company for the purpose of the Takeovers Code. On the basis of 872,022,780 Shares in issue as at the Latest Practicable Date and assuming no further issue or repurchase of Shares prior

APPENDIX I EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE

to the date of the AGM and assuming that there will not be any change in the issued share capital of the Company prior to the repurchase of Shares, in the event that the Repurchase Mandate was exercised in full, their interests in the Company as a concert party group with respect to the Company will be further increased to approximately 57.36%. On the basis of the aforesaid increase of shareholding, the Directors are not presently aware of any consequences which would arise under the Takeovers Code as a consequence of any repurchases pursuant to the Repurchase Mandate.

The Directors have no intention to exercise the Repurchase Mandate to such an extent that will result in the number of Shares in hands of public falling below the prescribed minimum percentage of 25%.

SHARE REPURCHASE MADE BY THE COMPANY

The Company bought back an aggregate of 3,212,000 Shares on the Stock Exchange during the six months preceding the Latest Practicable Date, details of which are as follows:

Date (dd/mm/yyyy)	No. of Shares repurchased	Highest price paid per Share (HKD)	Lowest price paid per Share (HKD)	Total Amount Paid (HKD)
3 January 2019	670,000	4.50	4.32	2,975,600
7 January 2019	384,000	4.69	4.57	1,785,570
8 January 2019	200,000	4.74	4.66	945,500
9 January 2019	150,000	4.77	4.72	713,430
11 January 2019	280,000	5.02	5.00	1,402,490
14 January 2019	500,000	5.07	4.92	2,505,350
15 January 2019	500,000	5.10	4.95	2,513,310
16 January 2019	398,000	5.19	5.09	2,054,070
17 January 2019	10,000	5.18	5.18	51,800
18 January 2019	87,000	5.25	5.22	454,520
25 January 2019	33,000	5.45	5.42	178,910
Total	3,212,000			15,580,550

Saved as disclosed herein, the Company had not repurchased any Shares in the six months preceding the Latest Practicable Date, whether on the Stock Exchange or otherwise.

SHARE PRICES

The highest and lowest closed prices at which the Shares were traded on the Stock Exchange during each of the twelve calendar months immediately preceding (and including) the Latest Practicable Date were as follows:

	Closed prices	
	Highest <i>HKD</i>	Lowest <i>HKD</i>
2018		
April	9.19	8.24
May	9.58	8.55
June	8.65	7.05
July	7.04	5.98
August	7.37	5.49
September	7.11	6.08
October	6.04	5.07
November	5.80	5.26
December	5.95	4.40
2019		
January	5.94	4.19
February	6.13	5.72
March	6.01	5.54
April (up to the Latest Practicable Date)	5.83	5.19

**APPENDIX II PARTICULARS OF THE DIRECTORS PROPOSED
FOR ELECTION OR RE-ELECTION AT THE AGM**

The particulars of Directors who are subject to election or re-election at the AGM and which are required to be disclosed under the Listing Rules are set out below:

Ms. CHEN Yujun

Ms. CHEN Yujun, aged 39, is our proposed independent non-executive Director with effect from the conclusion of the AGM. Subject to the approval by the Shareholders of the appointment of Ms. Chen as an independent non-executive Director, the Board also resolved to appoint Ms. Chen as the chairlady of the audit committee of the Company and as a member of the nomination committee of the Company at the conclusion of the AGM.

Ms. Chen has over 13 years of experience in auditing, accounting and corporate finance. She has been a member of the Chinese Institute of Certified Public Accountants since 2010 and obtained a bachelor's degree in arts and a bachelor's degree in management from Guangdong University of Foreign Studies (廣東外語外貿大學) in 2005. Ms. Chen has been the vice general manager of financial management center of Guangzhou Fineland Real Estate Development Co., Ltd. (廣州市方圓房地產發展有限公司) since February 2018. Prior to that, she worked with Shanghai Eyugame Network Technology Co., Ltd. (上海易娛網絡科技有限公司) as the chief financial officer from March 2016 to February 2018; worked with the Group as the chief financial officer from April 2014 to March 2016 and as deputy chief financial officer from May 2013 to March 2014; worked with KPMG in the audit department from July 2005 to May 2012 at various posts.

As at the Latest Practicable Date, Ms. Chen did not have any interests in the Shares within the meaning of Part XV of the SFO.

Subject to the Shareholders' approval at the AGM, Ms. Chen will enter into a letter of appointment with the Company to act as an independent non-executive Director for an initial term of three years commencing on the date of the AGM, subject to the rotation and re-election provisions in accordance with the articles of association of the Company and the Corporate Governance Code of the Listing Rules, and can be terminated by the Company or Ms. Chen by giving not less than three months' notice in writing or in other ways in accordance with the terms of the service agreement. Pursuant to the terms of the service agreement, Ms. Chen will receive a director's fee of HKD150,000 per year, which is determined with reference to the market rate and her time, effort and expertise to be devoted to the Company's affairs and the Company's remuneration policy.

Ms. Chen is not connected with any existing Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Mr. AN Yubao

Mr. AN Yubao (安郁寶), aged 76, is our chairman and an executive Director and a controlling shareholder. He was appointed as our Director with effect from 24 January 2011. He is also a director of Guangzhou Consun Pharmaceutical Company Limited (“**GZ Consun**”), Consun Pharmaceutical (Inner Mongolia) Co., Ltd. (“**Inner Mongolia Consun**”) and Guangxi Yulin Pharmaceutical Group Co., Ltd. (“**Yulin Pharmaceutical**”), and a director and the legal representative of Guangzhou Consun Pharmaceutical Research Company Limited (“**Consun Research**”). As at the Latest Practicable Date, each of GZ Consun, Inner Mongolia Consun and Consun Research is a wholly-owned subsidiary of the Company, while the Company is a controlling shareholder of Yulin Pharmaceutical, holding 72.69% of equity interest. Mr. An is primarily responsible for the overall management, operations, investment and the charting and reviewing of corporate directions and strategies of our Group.

Mr. An has nearly 20 years of experience in medical education and over 20 years of experience in the business of the pharmaceutical industry. He has served various key positions, including executive director of GZ Consun since its establishment. Mr. An served as the vice chairman of 廣東南方李錦記商貿信息中心 (Guangdong Southern Lee Kum Kee Commercial Information Centre) from November 1995 to February 1999. From July 1996 to December 1998, Mr. An started his career in the pharmaceutical industry by serving as the chairman and legal representative of 廣東南方李錦記營養保健品有限公司 (Guangdong Southern Lee Kum Kee Nutrition Health Products Co., Ltd.) and representing 中國人民解放軍第一軍醫大學 (the First Military Medical University of the People’s Liberation Army of the PRC) as one of its shareholders. Mr. An served as the minister and vice president respectively of 南方醫科大學 (原中國人民解放軍第一軍醫大學) (Southern Medical University) (formerly known as the First Military Medical University of the People’s Liberation Army of the PRC) from November 1991 to August 2001 and served as the vice president of 中國人民解放軍濟南軍區總醫院 (Jinan Military General Hospital of the People’s Liberation Army of the PRC) from 1987 to 1988. Between 1981 and 1987, Mr. An worked at various units of the PRC People’s Liberation Army and was mainly responsible for hygiene and hospital management.

Mr. An graduated from 中國人民解放軍後勤學院 (the Logistics Engineering College of the People’s Liberation Army of the PRC) in 1981 and majored in rear commanding. Mr. An also obtained a master’s degree in business administration from Asia International Open University (Macau) (now known as City University of Macau) in November 2007.

As at the Latest Practicable Date, Mr. An held 9,805,817 Shares and was deemed to be interested in 197,324,000 Shares held by Central Success Developments Limited. The entire issued share capital of Central Success Developments Limited was owned by Aali Resources Limited which was held in the name of BOS Trustee Limited as a trustee of a discretionary trust of which Mr. An was the founder. Further, Mr. An was also interested in 18,750,000 Share Options (of which 8,750,000 Share Options were subject to Shareholders’ approval) under the SFO. Save as disclosed, as at the Latest Practicable Date, Mr. An did not have any interests in the Shares within the meaning of Part XV of the SFO.

APPENDIX II PARTICULARS OF THE DIRECTORS PROPOSED FOR ELECTION OR RE-ELECTION AT THE AGM

Mr. An has entered into a service agreement with the Company with a term of three years commencing from the Listing Date and is subject to retirement by rotation and re-election at the AGM in accordance with the Articles of Association. He is entitled to RMB2,380,000 as annual salary. The remuneration committee of the Company will make recommendations to the Board on the remuneration and compensation packages with reference to his responsibilities, work load, the time devoted to the Group and the performance of the Group. The principal elements of his remuneration package include salary and allowance, but exclude discretionary bonus.

As disclosed in the circular of the Company dated 20 March 2017, Mr. An, Ms. Li and Mr. Young have entered into an acting in concert agreement which was terminated by a deed of termination on 16 December 2016. As at the Latest Practicable Date, Mr. An, Ms. Li and Mr. Young were acting in concert and they had not made a submission to obtain confirmation from the SFC that they were no longer acting in concert pursuant to note 3 to the definition of “acting in concert” of the Takeovers Code. Save as disclosed above, Mr. An is not connected with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Ms. LI Qian

Ms. LI Qian (黎倩), aged 54, is our vice chairlady, an executive Director and chief executive officer and a controlling shareholder. She was appointed as our Director with effect from 24 December 2012. She is also the chairlady of GZ Consun, and a director of Inner Mongolia Consun and Yulin Pharmaceutical, primarily responsible for formulating and implementing the corporate strategies, overseeing production activities, business development, research and administrative management of our Group.

Ms. Li has over 28 years of experience in the business of pharmaceutical industry. Prior to joining our Group, Ms. Li worked at Southern Medical University from October 1989 to April 1998. Ms. Li joined our Group in 1997 when Consun Pharmaceutical was newly set-up, as the associate director of general manager’s office, human resources manager, deputy executive general manager and deputy sales general manager of GZ Consun. Ms. Li has also served as a director and the general manager (which was redesignated as president in May 2008) of GZ Consun since November 1999. Ms. Li obtained a master’s degree in business administration at Asia International Open University (Macau) in November 2007. She has obtained 3 invention patents and published research papers on the “Chinese journal of Clinical Medicine” (《中國臨床醫學雜誌》). Ms. Li was awarded as Excellent Private Entrepreneur (優秀民營企業家) by Tongliao City People’s Government of the Inner Mongolia Autonomous Region in July 2008, and a Model Worker (勞動模範) by Inner Mongolia People’s Government in April 2010. In December 2010, she obtained the Third Prize for Technological Progress in the Inner Mongolia Autonomous Region (內蒙古自治區科技進步三等獎). In December 2011, she was recognised as Famous Entrepreneur in Pharmaceutical Industry of Guangdong Province (廣東省醫藥行業著名企業家) by Guangdong Province Pharmaceutical Industry Association (廣東省醫藥行業協會). In April 2014, she was elected as Chinese Pharmaceutical

APPENDIX II PARTICULARS OF THE DIRECTORS PROPOSED FOR ELECTION OR RE-ELECTION AT THE AGM

Brand Woman (中國(醫藥行業)品牌女性). In February 2017, she was accredited as Excellent Entrepreneur in Pharmaceutical Industry of Guangdong Province (廣東省醫藥行業優秀企業家) and in December 2017 was awarded the “Best Business Leader Award” by “China Finance”.

Ms. Li has entered into a service agreement with the Company with a term of three years commencing from the Listing Date and is subject to retirement by rotation and re-election at the AGM in accordance with the Articles of Association. She is entitled to RMB2,280,000 as annual salary. The remuneration committee of the Company will make recommendations to the Board on the remuneration and compensation packages with reference to his responsibilities, work load, the time devoted to the Group and the performance of the Group. The principal elements of his remuneration package include salary and allowance, but exclude discretionary bonus.

As at the Latest Practicable Date, 5,922,261 Shares were held by Ms. Li and 127,048,000 Shares were held by Double Grace International Limited. Double Grace International Limited was wholly owned by Ms. Li. Further, Ms. Li was also interested in 18,750,000 Share Options (of which 8,750,000 Share Options were subject to Shareholders’ approval) under the SFO. Save as disclosed, as at the Latest Practicable Date, Ms. Li did not have any interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above in the section “Mr. AN Yubao” in this Appendix, Ms. Li is not connected with any existing Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Professor ZHU Quan

Professor ZHU Quan (朱荃), aged 79, is our executive Director. He was appointed as our Director with effect from 24 December 2012. Professor Zhu is also a director and the chief scientist of GZ Consun and the general manager of Consun Research. Professor Zhu joined our Group in August 2006 as the chief scientist of GZ Consun. Professor Zhu is primarily responsible for the product research and development of our Group.

Professor Zhu has over 30 years of experience in teaching and research at medical school and over 10 years of experience in the business of pharmaceutical industry. Professor ZHU has served as professor and Ph.D. candidate supervisor at 澳門科技大學 (Macau University of Science and Technology) since September 2003. He served various positions, such as a deputy director of medicine department, a director of 國家規範化中藥藥理實驗室 (National Standardization Laboratory for Chinese Herbal Pharmacology), a Ph.D. candidate supervisor at 南京中醫藥大學 (Nanjing University of Chinese Medicine) between October 1981 and November 2005. Professor ZHU also served as an expert for 國家教育部科學技術委員會 (Science & Technology Commission of Ministry of Education), an assessment expert for 國家自然科學基金生命科學部 (Department of Life Science of National Natural Science Foundation) and a drug evaluation expert in Jiangsu Province and in the PRC.

APPENDIX II PARTICULARS OF THE DIRECTORS PROPOSED FOR ELECTION OR RE-ELECTION AT THE AGM

Professor Zhu graduated from 中醫科學院 (China Academy of Traditional Chinese Medicine) (now known as 中國中醫科學院 (China Academy of Chinese Medical Sciences)) in November 1981 with a master's degree in pharmacology of traditional Chinese medicine.

As at the Latest Practicable Date, save that Professor Zhu was interested in 3,757,700 Share Options of the Company, he did not have any interests in the Shares within the meaning of Part XV of the SFO.

Professor Zhu has entered into a service agreement with the Company with a term of three years commencing from the Listing Date and is subject to retirement by rotation and re-election at the AGM in accordance with the Articles of Association. He is entitled to RMB1,200,000 as annual salary. The remuneration committee of the Company will make recommendations to the Board on the remuneration and compensation packages with reference to his responsibilities, work load, the time devoted to the Group and the performance of the Group. The principal elements of his remuneration package include salary and allowance, but exclude discretionary bonus.

Professor Zhu is not connected with any existing Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Mr. TANG Ning

Mr. TANG Ning (唐寧), aged 53, is our executive Director. He was appointed as our Director with effect from 1 June 2018. He is also a director and vice president of GZ Consun. Mr. Tang joined the Group in July 1998 as a business manager. Between July 1998 and June 2011, Mr. Tang served various positions at GZ Consun, such as business manager, regional marketing manager, marketing and sales director, and president assistant. He has been the vice president of GZ Consun since June 2011. Prior to joining the Group, Mr. Tang worked in wholesale commercial trade of textiles products at Zhangjiajie City in Hunan Province between October 1987 and June 1998. Mr. Tang graduated from Hunan Business Management Cadre College (湖南商業管理幹部學院) in June 1986 with a major in marketing business economics.

Mr. Tang has entered into a service agreement with the Company to act as an executive Director for a term of three years commencing from 1 June 2018, subject to the rotation provisions in accordance with the articles of association of the Company, and can be terminated by the Company or Mr. Tang by giving not less than three months' notice in writing or in other ways in accordance with the terms of the service agreement. According to Mr. Tang's service agreement with the Company, Mr. Tang will receive a director's fee or emolument and performance-based bonus, which will be determined by the Board based on recommendation made by the Board's remuneration committee with reference to his performance. Mr. Tang received RMB549,000 as salaries and RMB373,000 as performance-based bonus for the year ended 31 December 2018.

**APPENDIX II PARTICULARS OF THE DIRECTORS PROPOSED
FOR ELECTION OR RE-ELECTION AT THE AGM**

As at the Latest Practicable Date, save that Mr. Tang was interested in 2,805,600 Share Options under the SFO, he did not have any interests in Shares within the meaning of Part XV of the SFO.

Mr. Tang is not connected with any existing Directors, senior management, substantial shareholders or controlling shareholders of the Company.

There are no other matters relating to the election and re-election of the Directors that need to be brought to the attention of the Shareholders or to be disclosed pursuant to Rules 13.51(2) of the Listing Rules.

NOTICE OF AGM



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1681)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that an annual general meeting of Consun Pharmaceutical Group Limited (the “**Company**”) will be held at United Conference Centre, 10th Floor, United Center, 95 Queensway, Admiralty, Hong Kong, on 31 May 2019 (Friday), at 10:00 a.m. for the following purposes:

1. To receive and approve the audited consolidated financial statements together with the directors’ report and the independent auditor’s report of the Company for the year ended 31 December 2018.
2.
 - (a) To elect Ms. CHEN Yujun as an independent non-executive director of the Company.
 - (b) To re-elect Mr. AN Yubao as an executive director of the Company.
 - (c) To re-elect Ms. LI Qian as an executive director of the Company.
 - (d) To re-elect Professor ZHU Quan as an executive director of the Company.
 - (e) To re-elect Mr. TANG Ning as an executive director of the Company.
 - (f) To authorise the board of directors of the Company (the “**Directors**”) to fix the Directors’ remuneration.
3. To declare and pay to the shareholders of the Company a final dividend of HKD0.2 per ordinary share of the Company for the year ended 31 December 2018.
4. To re-appoint KPMG as auditors of the Company and to authorise the board of Directors to fix their remuneration.

NOTICE OF AGM

As special business, to consider and, if thought fit, pass with or without amendments, the following resolutions as ordinary resolutions:

5. **“THAT:**

- (a) subject to paragraph (c) below, and pursuant to the Rules Governing the Listing of Securities (the **“Listing Rules”**) on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**), the exercise by the Directors during the Relevant Period (as hereinafter defined in this resolution) of all the powers of the Company to allot, issue and deal with any unissued shares in the capital of the Company and to make or grant offers, agreements and options (including but not limited to warrants, bonds and debentures convertible into shares of the Company) which might require the exercise of such power be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) shall authorise the Directors during the Relevant Period (as hereinafter defined) to make or grant offers, agreements and options (including warrants, bonds and debentures convertible into shares of the Company) which might require the shares in the capital of the company to be issued either during or after the end of the Relevant Period (as hereinafter defined);
- (c) the total number of shares of the Company allotted or agreed conditionally or unconditionally to be allotted or issued (whether pursuant to an option or otherwise) by the Directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to (i) a Rights Issue (as hereinafter defined); or (ii) an issue of shares upon the exercise of options which may be granted under any share option scheme or under any option scheme or similar arrangement for the time being adopted for the grant or issue to officers and/or employees of the Company and/or any of its subsidiaries or any other person of shares or rights to acquire shares of the Company; or (iii) any scrip dividend schemes or similar arrangements providing for the allotment and issue of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the Articles of Association of the Company; or (iv) a specific authority granted by the shareholders of the Company in general meeting, shall not exceed 20% of the total number of issued shares of the Company at the date of the passing of this resolution and the said approval shall be limited accordingly; and
- (d) for the purpose of this resolution,

“Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;

NOTICE OF AGM

- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association of the Company or any applicable laws of the Cayman Islands to be held; or
- (iii) the passing of an ordinary resolution by shareholders of the Company in general meeting revoking, varying or renewing the authority given to the Directors by this resolution; and

“Rights Issue” means an offer of shares of the Company or issue of option, warrants or other securities giving the right to subscribe for shares of the Company, open for a period fixed by the Directors to holders of shares whose names appear on the register of members of the Company (and, where appropriate, to holders of other securities of the Company entitled to the offer) on a fixed record date in proportion to their then holdings of such shares (or, where appropriate, such other securities) (subject in all cases to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory applicable to the Company).”

6. **“THAT:**

- (a) subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as hereinafter defined) of all powers of the Company to repurchase shares of the Company on the Stock Exchange or on any other stock exchange on which the shares of the Company may be listed and which is recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose, subject to and in accordance with all applicable laws and/or the requirements of the Listing Rules or of any other stock exchange as amended from time to time, be and is hereby generally and unconditionally approved;
- (b) the total number of shares of the Company which the Company is authorised to repurchase pursuant to the approval in paragraph above during the Relevant Period (as hereinafter defined) shall not exceed 10% of the total number of issued shares of the Company at the date of the passing of this resolution, and the authority granted pursuant to paragraph (a) above shall be limited accordingly; and

NOTICE OF AGM

- (c) for the purposes of this resolution, “Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:
- (i) the conclusion of the next annual general meeting of the Company; or
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association of the Company or any applicable laws of the Cayman Islands to be held; or
 - (iii) the passing of an ordinary resolution by shareholders of the Company in general meeting revoking, varying or renewing the authority given to the Directors by this resolution.”
7. “**THAT** conditional upon the ordinary resolutions set out in paragraphs 5 and 6 of the notice convening this meeting being passed, the general mandate granted to the Directors to allot, issue and deal in any unissued shares pursuant to the ordinary resolution set out in paragraph 5 of the notice convening this meeting be and is hereby extended by the addition to the total number of shares of the Company which may be allotted or agreed conditionally or unconditionally to be allotted by the Directors pursuant to such general mandate of an amount representing the total number of shares of the Company repurchased by the Company under the authority granted pursuant to the ordinary resolution set out in paragraph 6 of the notice convening this meeting, provided that such extended amount shall not exceed 10% of the total number of issued shares of the Company at the date of the passing of this resolution.”

By Order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman and Executive Director

Hong Kong, 30 April 2019

NOTICE OF AGM

Notes:

1. A member entitled to attend and vote at the above meeting (or at any adjournment thereof) (the “AGM”) shall be entitled to appoint another person as his proxy to attend and, on a poll, vote in his stead. A member who is the holder of two or more Shares may appoint more than one proxy to represent him and, on a poll, vote on his behalf. A proxy need not be a member of the Company.
2. In order to be valid, a proxy form together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power or authority, must be deposited at the share registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 48 hours before the time for holding the meeting or any adjournment thereof.
3. The register of members of the Company will be closed from Tuesday, 28 May 2019 to Friday, 31 May 2019, both days inclusive, during which period no transfer of shares will be registered. In order to determine the eligibility of the shareholders who are entitled to attend and vote at the AGM, all duly completed transfer forms accompanied by the relevant share certificates must be lodged with the Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Monday, 27 May 2019.
4. To determine shareholders’ entitlements to the proposed final dividend relating to proposed resolution no.3 in this notice, the register of members of the Company will be closed from Tuesday, 11 June 2019 to Friday, 14 June 2019 (both days inclusive), during which period no share transfer will be registered. In order to qualify for the proposed final dividend, all share transfers accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, not later than 4:30 p.m. on Monday, 10 June 2019.
5. According to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at general meeting of the Company must be taken by poll. Therefore, all proposed resolutions put to the vote at the AGM will be taken by way of poll and the Company will announce the results of the poll in the manner prescribed under Rule 13.39(5) of the Listing Rules.
6. With regard to proposed resolution nos. 2, 5 to 7 in this notice, a circular giving details of the electing and re-electing of Directors and general mandates to issue and to repurchase Shares will be despatched to Shareholders. The biographical details of the Directors who are subject to election or re-election at the meeting are set out in Appendix II to the circular.
7. As at the date of this notice, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.